ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1152

Nailfold Videocapillaroscopy Abnormalities in Different Autoimmune Inflammatory Myopathy Subsets

Thaisa Cotton1, Valérie Leclair2, Claudie Berger3, Yves Troyanov4, marie Hudson2 and Geneviève Gyger2, and Canadian Inflammatory Myopathy Study (CIMS), 1Université de Montréal, Montreal, QC, Canada, 2McGill University, Montreal, QC, Canada, 3Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 4Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada

Meeting: ACR Convergence 2024

Keywords: Biomarkers, dermatomyositis, Imaging, Myopathies, Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Nailfold videocapillaroscopy (NVC) alterations have mostly been described in autoimmune inflammatory myopathies (AIM) classified using Bohan and Peter criteria. The aim of this study was to describe NVC abnormalities in AIM subsets using contemporary sero-clinico-pathological criteria and explore the utility of current NVC patterns in AIM. 

Methods: We studied AIM subjects in the Canadian Inflammatory Myopathy Study (CIMS), an early onset cohort followed prospectively. NVC images were acquired using the DS MEDICA Videocap (X200 magnification). The nailfolds of the second, third, fourth and fifth fingers of both hands were photographed and scored by an experienced rheumatologist. Microhemorrhages, giant capillaries, ectasias and ramified capillaries were scored using a standardized semi-quantitative scale (0 = no, 1 = ≤33%, 2= 33–66%, and 3 = ≥66% abnormalities per linear millimeter). Capillary density was scored semi-quantitatively (0 if ≥7, 1 if 4–6, or 2 if ≤3 capillaries/mm) and quantitatively (mean number of capillaries/mm). Each NVC parameter, as well as giant-ramified capillaries, were scored as present or absent. Finally, NVC patterns (i.e., scleroderma, sleroderma-like, late scleroderma, non-specific, and normal) were assigned. NVC features and patterns were compared between AIM subsets.

Results: We included 100 AIM subjects: 41 dermatomyositis (DM), 24 scleromyositis (SM), 16 anti-synthetase syndrome (ASyS), 7 immune-mediated necrotizing myopathy (IMNM), 8 inclusion body myositis (IBM), 3 polymyositis (PM) and 1 overlap myositis (Table 1). Of those, 71% were female, and median disease duration of 0.9 years. In the cohort, 45% of subjects had abnormal NVC, 25% non-specific NVC , and 29% normal NVC patterns. When NVC features were compared between AIM subsets (Table 2), DM and SM had the lowest capillary densities (5.7 capillaries/mm and 5.3 capillaries/mm, respectively, p< 0.001). NVC abnormalities were frequent in DM, ASyS and SM, although median semi-quantitative scores showed that abnormalities were found in less than 33% of capillaries studied. NVC patterns were not discriminant for DM, ASyS and SM, with scleroderma-like, scleroderma-active and non-specific patterns described in those 3 subsets. Apart from ramified capillaries, NVC abnormalities were infrequent in IMNM, IBM and PM.

Conclusion: In this cohort of AIM subjects classified using a sero-clinico-pathological approach, DM, ASyS and SM showed frequent NVC abnormalities, although no NVC pattern of abnormalities was associated with a particular subset demonstrating that current NVC pattern descriptions are not useful for AIM subsetting.

Supporting image 1

Table 1

Supporting image 2

Table 2


Disclosures: T. Cotton: None; V. Leclair: None; C. Berger: None; Y. Troyanov: AbbVie/Abbott, 1, 2, 6, AstraZeneca, 1, 2, 6, Boehringer-Ingelheim, 1, 2, 6, Eli Lilly, 1, 2, 6, GlaxoSmithKlein(GSK), 1, 2, 6, Inflarx, 1, 2, 6, Kezar Life Sciences, 1, 2, 6, Sobi, 1, 2, 6, UCB, 1, 2, 6; m. Hudson: AstraZeneca, 5, Boehringer-Ingelheim, 5, Bristol-Myers Squibb(BMS), 5, Pfizer, 5; G. Gyger: AbbVie/Abbott, 1, Frenesius Kabi, 1, Janssen, 1.

To cite this abstract in AMA style:

Cotton T, Leclair V, Berger C, Troyanov Y, Hudson m, Gyger G. Nailfold Videocapillaroscopy Abnormalities in Different Autoimmune Inflammatory Myopathy Subsets [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/nailfold-videocapillaroscopy-abnormalities-in-different-autoimmune-inflammatory-myopathy-subsets/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nailfold-videocapillaroscopy-abnormalities-in-different-autoimmune-inflammatory-myopathy-subsets/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology